<?xml version="1.0" encoding="UTF-8"?>
<p id="p0070">SARS-CoV-2 Infection in individuals with DM is expected to trigger higher stress conditions, with greater release of hyperglycemic hormones, e.g., glucocorticoids and catecholamines, leading to increased blood glucose levels and abnormal glucose variability 
 <xref rid="b0130" ref-type="bibr">[26]</xref>. On the other hand, according to a retrospective study from Wuhan some 10% COVID-19-positive patients with T2DM suffered at least one hypoglycemic event (&lt;3.9Â mmol/L) 
 <xref rid="b0135" ref-type="bibr">[27]</xref>. Notoriously, hypoglycemia mobilizes pro-inflammatory monocytes and increases platelet reactivity, thus contributing to a higher cardiovascular mortality in patients with DM 
 <xref rid="b0140" ref-type="bibr">[28]</xref>.
</p>
